Azitra Inc (AZTR) Q4 2024 Earnings Report

Azitra Inc (AZTR) reported a Q4 2024 revenue of $7.4925 million against substantial operating expenses driven by preclinical R&D and general/administrative spending. While gross profit was positive at $7.7213 million, the quarter shows a stark contrast between revenue and the magnitude of research and administrative outlays, resulting in a negative EBITDA of approximately $10.98 billion and a net income of about -$2.39 million. The scale of R&D (approximately $4.72 billion) and G&A (approximately $6.26 billion) dominates the cost structure, reflecting the company’s preclinical, pipeline-centric business model rather than a traditional commercial biotech with near-term product revenue. This dynamic yields a deep quarterly operating loss and sizable cash burn, despite a modest cash balance of roughly $4.55 million at quarter-end.

From a liquidity perspective, Azitra generated negative cash flow from operations (-$2.59 million) and ended the period with net cash used of approximately -$2.70 million for the quarter, reducing the cash balance to about $4.55 million. The balance sheet remains lean: total assets around $7.36 million, total liabilities about $1.66 million, and stockholders’ equity near $5.70 million, with a net debt position of about -$3.999 million (i.e., cash exceeds debt).

The earnings profile is heavily dependent on ongoing preclinical program activity and eventual value realization through partnerships, licensing, or product-stage milestones. With no formal forward-looking revenue guidance disclosed in the data, the near-term investment thesis centers on the potential value creation from Azitra’s ATR programs (ATR12, ATR04, and ATR01) and the company’s ability to secure strategic collaborations that could extend runway and de-risk clinical milestones. Investors should monitor progress in preclinical data, interim program updates, and capital-raising activity, which will be critical to sustaining operations given the current burn rate.